FDA 483 - Kolmar Korea Co., Ltd. Bucheon Factory - December 06, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspection of Kolmar Korea Co., Ltd. revealed significant deficiencies in their manufacturing of OTC drug products, primarily concerning laboratory controls and quality unit procedures. The firm failed to thoroughly investigate discrepancies and out-of-specification results, lacked proper verification of test methods, and maintained incomplete laboratory records. Additionally, the quality control unit's responsibilities were not adequately defined or followed, impacting data review, change control, and sampling processes.
ID · 3ff86cfd-2786-4273-b456-54bb99aabd4a